Can Legalizing Cannabis Help with the Opioid Epidemic?
Two studies came out earlier this week in JAMA Internal Medicine stating that there is a potential link between cannabis legalization and a decrease in the amount of prescriptions for opioids (1,2). The first study by Bradford and colleagues concluded that medical cannabis laws were associated with significant reductions in opioid prescriptions for patients in the Medicare Part D population. “This finding was particularly strong in states that permit dispensaries, and for reductions in hydrocodone and morphine prescriptions,” the authors stated.
According to the study (1), this longitudinal analysis of Medicare Part D found that prescriptions filled for all opioids decreased by 2.11 million daily doses/year from an average of 23.08 million daily doses/year when a state instituted any medical cannabis law. Prescriptions for all opioids decreased by 3.742 million daily doses/year when medical cannabis dispensaries opened.
The second paper by Wen and Hockenberry was a population-based, cross-sectional study based on the all-capture Medicaid prescription data from 2011 to 2016. The authors compared the Medicaid prescription data to the medical marijuana and adult-use marijuana laws that were passed during the same time frame to discover if those laws were associated with lower opioid prescribing rates. According to the study, the state implementation of medical marijuana laws was associated with a 5.88% lower rate of opioid prescriptions and the implementation of adult-use marijuana laws was associated with a 6.38% lower rate of opioid prescriptions.
“These findings suggest that medical and adult-use marijuana laws have the potential to reduce opioid prescribing for Medicaid enrollees, a segment of population with disproportionately high risk for chronic pain, opioid use disorder, and opioid overdose,” said the authors (2).
Both of these studies strongly indicate that cannabis can help fight the opioid epidemic. For more information on these studies, please see the full articles at the links provided below.
References:
- A.C. Bradford, W.D. Bradford, A. Abraham, and G. Bagwell Adams, JAMA Intern Med. doi:10.1001/jamainternmed.2018.0266 (2018). Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2676999
- H. Wen and J.M. Hockenberry, JAMA Intern Med. doi:10.1001/jamainternmed.2018.1007 (2018). Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2677000
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
